A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

One of the hallmarks of Alzheimer's is the development of amyloid plaques in the brain, which occurs when a naturally ...

There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for widespread use in the health service in England after the health spending ...

Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...

Donanemab was evaluated in a main study (Phase III Study TRAILBLAZER-ALZ 2) involving 1,736 patients with early Alzheimer’s disease who had mild cognitive impairment, mild dementia and evidence ...

Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.

The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...

Donanemab, also known as Kisunla, has recently been licensed as a treatment for early-stage Alzheimer’s disease in the UK. However, donanemab has not been recommended for use in the NHS. Here's what ...